Our Vision and Values

Nature gives us the elements, we add the science, patients reap the benefits.

Creating a paradigm shift in the biopharma market

By returning to and honing the knowledge and tools that have been part of humanity’s pharmacopeia since the advent of civilisation. MGC Pharma is reaching back to our roots to create the future – one consisting of sustainable and affordable treatment options that work with patients’ internal systems, to ease their symptoms and facilitate lifestyles that are empowered by medication as opposed to limited by it.

Driven by people who want to make a change

Brought to the level of API (Active Pharmaceutical Ingredient) through a careful and regulated process of isolation and purification. These are the building blocks of MGC’s medicines, and we believe they hold the key to more effective treatments for patients around the world.
Our vision is to have a global impact on undertreated medical conditions and diseases, using the power of plant-based medicine in novel combinations by using technology to harness knowledge and science to achieve our “Nature to Medicine” strategy.

Roby Zomer
Co-Founder & CEO

We live by our values


At the core of any medicine is the question of how well it works. MGC Pharma invests significant resources in ensuring a clinical agenda for each product to ensure the final product going to market maximises the existing potential of our core ingredients.


When a medicine works the first time, it needs to work the same way every time a patient takes it. To ensure this consistency, MGC Pharma has built a pipeline that runs from: Genetics, through to raw ingredient manufacture, to the highest level of pharmaceutical manufacturing possible. With patients potentially using these treatments for decades, MGC will ensure the last bottle will be exactly like the first.


Patients around the world are finding themselves mortgaging their futures to keep themselves alive today. This is an untenable, unjust and unfair situations. MGC Pharma is constantly seeking modalities that will enable the company to tackle high-cost treatments with affordable solutions.


Our world is rapidly changing, which includes global shifts in supply chains and access to ingredients through unforeseen changes. MGC Pharma seeks to create sustainable and viable solutions for the long-term production of our raw products in an earth friendly, globally responsible, manner.


Operating in an emerging industry means that every day is full of choices that challenge the set course. Legislation, access, investments are all moving targets as the world accepts these new treatments and their potential impact on public health. MGC Pharma exists as a dynamic global operation with the ability to rapidly enter new markets and identify viable course of treatment in keeping with local demands.


A company that is focused on innovation and creation cannot exist without revelling in its discoveries and pushing the envelope on what it believes it can achieve. MGC tries to foster a sense of wonder and amazement at what we can achieve in all of our team, and to acknowledge the privilege of working on a brave new frontier.

Leading the global shift towards plant-based, naturally harmonious medicines, improving lives and public health.

Rob Clements

Chief Commercial Officer

After starting his career with an initial spell in the City of London Rob joined the pharmaceutical industry in 1991. Over the following decade he progressed rapidly through field roles to Marketing Management. He then established his own consultancy specialising in relationship marketing and product launch for healthcare companies.

He subsequently worked in business development roles identifying potential product acquisitions – both prescription and OTC – the development and launch of medical devices and general strategic functions. His roles included improving business performance and company morale, and oversight of companies’ core marketing of ethical brands.

From 2011 Rob headed a pan-national team for Forest Laboratories delivering new ethical products to markets alongside management of the existing portfolio. As Director both of Marketing and Commercial operations he was also directly responsible for budgeting, planning and data provision, whilst remaining closely involved with the assessment of BD opportunities.

An expert in specialist disease marketing and business development Rob has also worked extensively on a number of proposed private equity asset buyouts in addition to previous consultancy work.

From 2019 he worked with Healthcare at Home (now Sciensus Rare) to help establish an international rare medicines division. As Vice President of Business Development his role included ongoing development and refinement of the service offering and building new business opportunities; from strategic partnerships and potential MA acquisitions through to establishing Sciensus Rare’s global footprint.